|
|
Sarepta Therapeutics Inc (NASDAQ: SRPT) |
|
Price: $20.9400
$-1.08 
-4.905%
|
| Day's High:
| $21.81999969482422
| Week Perf:
| -8.92 %
|
| Day's Low: |
$ 20.83 |
30 Day Perf: |
14.93 % |
| Volume (M): |
429,520 |
52 Wk High: |
$ 25.32 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$19.43 |
| Open: |
$21.81 |
52 Wk Low: |
$14.68 |
|
|
| Market Capitalization (Millions $) |
2,208 |
| Shares
Outstanding (Millions) |
105 |
| Employees |
835 |
| Revenues (TTM) (Millions $) |
1,974 |
| Net Income (TTM) (Millions $) |
-137 |
| Cash Flow (TTM) (Millions $) |
-49 |
| Capital Exp. (TTM) (Millions $) |
36 |
Business Description
Sarepta Therapeutics Inc is a biotechnology company that specializes in developing therapies for rare genetic diseases. The company is based in Cambridge, Massachusetts, and was founded in 1980.
Sarepta Therapeutics Inc focuses on developing and commercializing drugs for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disease that affects about 1 in every 3,500 males worldwide. The company's lead product candidate is a drug called eteplirsen, which is designed to treat DMD by repairing the genetic defects that cause the disease.
The company has a strong pipeline of other promising therapies, including drugs for the treatment of other types of muscular dystrophy and rare diseases such as limb-girdle muscular dystrophy, myotonic dystrophy, and spinal muscular atrophy.
Sarepta Therapeutics Inc has a robust research and development team made up of scientists, clinicians, and other experts with extensive experience in the field of genetic disease. The company has also built strong partnerships with academic institutions and other biotechnology companies, enabling it to access cutting-edge research and technology.
In addition to its drug development activities, Sarepta Therapeutics Inc is active in patient advocacy and education. The company works closely with patient advocacy groups and medical professionals to raise awareness about rare genetic diseases and to provide support to affected families. The company also sponsors research and educational programs, and provides financial assistance to families in need.
Sarepta Therapeutics Inc has a strong financial position, with a market capitalization of over $12 billion as of 2021, and a track record of revenue growth. The company has a broad investor base, including institutional investors, private equity firms, and individual investors.
Overall, Sarepta Therapeutics Inc is a successful biotechnology company that has made significant progress in developing therapies for rare genetic diseases. With its strong pipeline, experienced team, and commitment to patient advocacy, the company is well positioned for future growth and success.
Company Address: 215 First Street Cambridge 2142 MA
Company Phone Number: 274-4000 Stock Exchange / Ticker: NASDAQ SRPT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Thu, Jul 31 2025 2:05 PM UTC
Sarepta Therapeutics: Anticipating a Turnaround Amidst Financial Challenges CAMBRIDGE, Mass. Barricading the turbulent tides of fiscal challenges, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine, is poised to unveil its second quarter 2025 financial results. The announcement is slotted for release following the closure of the Nasdaq Glob...
|
| Business Update
Published Sat, Jul 26 2025 3:33 AM UTC
In the world of biopharmaceuticals, the intersection of innovative therapies and robust financial health is critical for sustained growth and development. Recent developments at Sarepta Therapeutics, a leader in precision genetic medicine, particularly in the treatment of rare diseases such as Duchenne muscular dystrophy (Duchenne), present a complex narrative that both capt...
|
| Business Update
Published Sat, Jul 19 2025 8:48 AM UTC
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a company specializing in precision genetic medicine for rare diseases, has recently gained attention due to two significant developments. On one hand, the company provided a statement regarding a request from the U.S. Food and Drug Administration (FDA) pertaining to its pioneering gene therapy, ELEVIDYS (delandistrogene moxeparvovec...
|
| Announcement
Published Thu, Jul 10 2025 3:02 PM UTC
Class Action Lawsuit Alert: Sarepta Therapeutics Investors Under the Microscope as Pomerantz LLP Takes Legal Action Overview In a series of unfolding legal developments, Pomerantz LLP, a reputable law firm specializing in securities litigation, has announced the launch of a class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent biotechnology com...
|
| Business Update
Published Wed, Jun 4 2025 2:11 PM UTC
CAMBRIDGE, Mass. Sarepta Therapeutics, Inc. (NASDAQ: SRPT), renowned for its pioneering work in precision genetic medicine for rare diseases, recently announced that the rAAVrh74 viral vector utilized in its investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) has received a platform technology designation from the U.S. Food and Drug Administration (FDA). T...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-1.79 $ |
| Revenues (TTM) |
18.73 $
|
| Cash Flow (TTM) |
- |
| Cash |
7.48 $
|
| Book Value |
14.49 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
2,364,484 |
| Net
Income per Employee (TTM) |
-163,743 |
| Receivable Turnover Ratio (TTM) |
5.04 |
| Inventory Turnover Ratio (TTM) |
0.01 |
| Asset Turnover Ratio (TTM) |
0.59 |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.79 $
|
| Revenues (TTM) |
18.73 $ |
| Cash Flow (TTM) |
- |
| Cash |
7.48 $
|
| Book Value |
14.49 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| US |
|
 49.87 % |
of total Revenue |
| PMO Products |
|
114.42 % |
of total Revenue |
| ELEVIDYS |
|
49.87 % |
of total Revenue |
| All Other Segments |
|
282.13 % |
of total Revenue |
| |
On January 8 2024 the Sarepta Therapeutics Inc provided following guidance
to be $175.8 million and $573.1 million, respectively.
Sarepta Therapeutics, a pioneering company in precision genetic medicine for rare diseases, announced its preliminaryn net product revenue for the fourth quarter and full-year 2023. The announcement was made during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
According to the preliminaryn and unaudited financial update, Sarepta Therapeutics expects the net product revenue for their flagship product, ELEVIDYS, to reach $175.8 million for the fourth quarter of 2023. The full-year net product revenue for ELEVIDYS is projected to be $573.1 million.
These estimates provide insights into the company's ...
|
|
|
